Biotech Showdown: Can Upstart Abivax Challenge Pharma Giant AbbVie in Immunology Race?
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
Zeta Global Holdings (NYSE: ZETA) is drawing increased attention from Wall Street, with multiple firms raising price targets amid early 2026 momentum. Analysts point to strategic AI partnerships and sector recovery prospects as key drivers.
A wave of subscription increases from Netflix, Disney, Apple, and others is forcing consumers to rethink their streaming budgets, with ad-supported tiers and strategic bundling emerging as key cost-saving strategies.
Microsoft shares tumbled 12% as investors questioned the return on its massive AI investments, despite strong cloud growth. The volatility has created a surge in bullish options activity, presenting strategic opportunities for long-term believers.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Despite a recent price target cut from Morgan Stanley, analysts maintain that Oracle's strategic investments in GPU-as-a-Service and its deepening ties with TikTok position it for long-term cloud growth, even as capital expenditures weigh on short-term earnings.
Wix.com Ltd. has launched a major share repurchase program as its stock trades near multi-year lows. While analysts have trimmed price targets, many maintain bullish ratings, citing significant upside potential and a more resilient outlook for SaaS companies in the face of AI disruption.
In a significant shift from its long-standing marketing playbook, Pizza Hut will not advertise during NBC's Super Bowl pre-game coverage this year, ending a tradition that spanned over a decade. The move comes as the chain undergoes a strategic review and reallocates its ad budget toward other sports and partnerships.
The Producer Price Index jumped 0.5% last month, more than double November's increase, as rising costs for machinery, metals, and travel services pointed to persistent pipeline pressures for consumers.
While an IRS extension grants an extra six months to file, experts caution that the April 15 payment deadline is non-negotiable. We break down the process, benefits, and common pitfalls for the millions considering this option.
Despite posting strong Q1 results and reaffirming its double-digit growth outlook for fiscal 2026, Intuit's stock has been caught in a broader software sector sell-off. Investors are grappling with whether AI poses a disruptive threat or a tangible growth catalyst for the financial software giant.
The global lifestyle retailer MINISO continues its aggressive capital return strategy, repurchasing millions of shares under a Rule 10b5-1 program as analysts remain bullish on the stock's outlook.
The Optimism Collective has unveiled OP Enterprise, a comprehensive blockchain infrastructure platform designed to give financial technology firms and institutions direct control over revenue and operations. The launch signals a pivotal shift towards institutional-grade Web3 solutions as regulatory clarity emerges.
Lean hog futures slipped lower on Friday, contrasting with a steady rise in the CME Lean Hog Index, as traders weighed softer cash prices against stronger wholesale pork values.
Bitcoin's rally to near $91,000 this week was abruptly halted as the U.S. dollar found its footing. The shift highlights the cryptocurrency's growing sensitivity to traditional macroeconomic forces and Federal Reserve policy speculation.
A week of significant stock swings saw Lockheed Martin and Texas Instruments surge on strong outlooks, while Humana plunged on regulatory headwinds. Here’s what drove the action and what analysts are saying.
While several stocks have posted impressive gains recently, not all momentum stories are built to last. We analyze one company with durable advantages and two where recent rallies may warrant skepticism.
While the financial sector remains the economy's cornerstone, policy headwinds have capped its recent performance. We analyze one credit rater and a fintech disruptor that show resilience, alongside a legacy asset manager facing challenges.
For long-term investors, volatility presents both opportunity and peril. We examine one stock with explosive potential and two others where caution may be warranted amid shifting market dynamics.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.